Is It Time to Rethink the Age-Old Practice of Permissive Hyperkalemia in Renin-Angiotensin-Aldosterone Inhibition?
Open Access
- 2 April 2021
- journal article
- editorial
- Published by Elsevier BV in Kidney International Reports
- Vol. 6 (5), 1203-1204
- https://doi.org/10.1016/j.ekir.2021.03.895
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Hyperkalemia and its Association With Mortality, Cardiovascular Events, Hospitalizations, and Intensive Care Unit Admissions in a Population-Based Retrospective CohortKidney International Reports, 2021
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet, 2019
- Sodium Zirconium Cyclosilicate among Individuals with HyperkalemiaClinical Journal of the American Society of Nephrology, 2019
- Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS InhibitorsJournal of Cardiovascular Pharmacology and Therapeutics, 2018
- Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or DiabetesAmerican Journal of Nephrology, 2017
- The Relation of Serum Potassium Concentration with Cardiovascular Events and Mortality in Community-Living IndividualsClinical Journal of the American Society of Nephrology, 2017
- Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney DiseaseJAMA, 2015
- Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trialEuropean Journal of Heart Failure, 2015
- Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With HyperkalemiaJAMA, 2014